Network Pharmacology and Experimental Verification of Si Shen Decoction Regulating FABP4/PPAR γ/NFκB Pathway in the Treatment of Collagen-induced Arthritis
CONCLUSION: SSD can relieve joint symptoms in CIA rats and alleviate inflammation by inhibiting the FABP4/PPARγ/NFκB signaling pathway. The effect of high-dose SSD was more prominent.PMID:38584563 | DOI:10.2174/0113862073296957240312090935 (Source: Combinatorial Chemistry and High Throughput Screening)
Source: Combinatorial Chemistry and High Throughput Screening - April 8, 2024 Category: Chemistry Authors: Rui Guan Jiashu Yao Qing Qi Jing Yu Ruoshi Liu Mingli Gao Source Type: research
Exploration of the molecular mechanism guiding Xinfeng capsule regulatory mechanism for rheumatoid arthritis inflammation
CONCLUSIONS: XFC could effectively improve the clinical inflammatory indexes of RA. The active ingredients of XFC improved the inflammatory state of RA by regulating the TLR-signaling pathway.PMID:38586085 | PMC:PMC10994809 | DOI:10.62347/TPOQ4910 (Source: American Journal of Translational Research)
Source: American Journal of Translational Research - April 8, 2024 Category: Research Authors: Ziheng Zhu Lei Wan Source Type: research
Network Pharmacology and Experimental Verification of Si Shen Decoction Regulating FABP4/PPAR γ/NFκB Pathway in the Treatment of Collagen-induced Arthritis
CONCLUSION: SSD can relieve joint symptoms in CIA rats and alleviate inflammation by inhibiting the FABP4/PPARγ/NFκB signaling pathway. The effect of high-dose SSD was more prominent.PMID:38584563 | DOI:10.2174/0113862073296957240312090935 (Source: Combinatorial Chemistry and High Throughput Screening)
Source: Combinatorial Chemistry and High Throughput Screening - April 8, 2024 Category: Chemistry Authors: Rui Guan Jiashu Yao Qing Qi Jing Yu Ruoshi Liu Mingli Gao Source Type: research
Next-Generation Anti-TNF α Agents: The Example of Ozoralizumab
AbstractBiologic therapy involving anti-tumor necrosis factor- α (anti-TNFα) agents has fundamentally changed the management of patients with immune-mediated inflammatory diseases, including rheumatoid arthritis, thus benefiting many patients. Nevertheless, the inability of some patients to achieve low disease activity or clinical remission remains a major co ncern. To address such concerns, next-generation anti-TNFα agents that differ from the immunoglobulin G-format anti-TNFα agents that have been used to date are being developed using antibody-engineering technology. Their unique design employing novel molecular cha...
Source: BioDrugs - April 8, 2024 Category: Drugs & Pharmacology Source Type: research
